Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -58.55M | -48.96M | -44.55M | -41.52M | -41.96M |
| Total Depreciation and Amortization | 3.00M | 4.15M | 4.09M | 3.89M | 2.36M |
| Total Amortization of Deferred Charges | 1.30M | -- | -- | -- | 1.40M |
| Total Other Non-Cash Items | 5.05M | 5.33M | 6.69M | 5.89M | 6.07M |
| Change in Net Operating Assets | 449.00K | -2.70M | -5.94M | -10.21M | 58.82M |
| Cash from Operations | -48.75M | -42.18M | -39.71M | -41.95M | 26.69M |
| Capital Expenditure | -2.11M | -2.35M | -1.94M | -2.88M | -2.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -138.71M | -18.99M | -129.13M | 38.40M | -11.79M |
| Cash from Investing | -140.82M | -21.34M | -131.07M | 35.51M | -14.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 200.52M | 45.77M | 237.77M | 1.62M | 7.00K |
| Repurchase of Common Stock | -15.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 15.00K | 0.00 | -15.00K | -- | -- |
| Cash from Financing | 200.52M | 45.77M | 237.75M | 1.62M | 7.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.95M | -17.75M | 66.98M | -4.81M | 12.32M |
